Analyst Casts Doubts On Merus' Lung Candidate Safety Profile

  • Earlier today, Merus N.V. MRUS announced the publication of the abstract highlighting interim data from the ongoing phase 1/2 trial of the bispecific antibody MCLA-129 in advanced non-small cell lung cancer (NSCLC) and other solid tumors. 
  • Needham says that the first clinical data readout from MCLA-129 suggests that the drug has a clinical profile comparable to Johnson & Johnson's JNJ Rybrevant (amivantamab). 
  • The analyst keeps the Buy rating and a price target of $45.
  • Also Read: Needham Says Merus' ASCO Update On Zeno 'Positive'
  • While available data are limited efficacy appears to be comparable, and MCLA-129 saw one ≥ Grade 3 infusion-related reaction, whereas the analyst had not seen any with amivantamab at the WCLC 2018 update. 
  • 13 patients were evaluable for response with preliminary signs of anti-tumor activity observed, including two partial responses (one confirmed) in EGFR mt NSCLC and four confirmed stable disease.
  • The analyst says that while expectations for MCLA-129 have come down, with the stock down ~20% over the past month, investors were looking for a competitive clinical profile.
  • Price Action: MRUS shares are up 1.71% at $19.66 on the last check Wednesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorBiotechNewsHealth CareSmall CapAnalyst RatingsGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!